Ocera Therapeutics, Inc.
OCRX
OCRX was delisted on the 8th of December, 2017.
0 hedge funds and large institutions have $0 invested in Ocera Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 21 closing their positions.
17.12% less ownership
Funds ownership: 17.12% → 0% (-17%)
100% less funds holding
Funds holding: 21 → 0 (-21)
100% less capital invested
Capital invested by funds: $5.17M → $0 (-$5.17M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 21
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$2.32M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$813K |
| 3 |
HP
Hikari Power
Tokyo,
Japan
|
-$771K |
| 4 |
VMI
VHCP Management II
New York
|
-$544K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$114K |
OCRX Hedge Fund Activity: Q4 2017 in Review
0 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Ocera Therapeutics, Inc. (OCRX) for Q4 2017, worth a combined $0 — down 100% from $5.17M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of OCRX and 0 opened new positions — a net loss of 21 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Perceptive Advisors, exiting entirely with an estimated $2.32M sold.
- 0 institutional investors held Ocera Therapeutics, Inc. (OCRX) as of Q4 2017, down from 21 in Q3 2017.
- Funds reported $0 of Ocera Therapeutics, Inc. stock for Q4 2017, down 100% quarter-over-quarter.
- 0 funds opened new Ocera Therapeutics, Inc. positions in Q4 2017 and 21 closed out, a net change of -21 holders.
- The largest Ocera Therapeutics, Inc. seller in Q4 2017 was Perceptive Advisors, an estimated $2.32M sold.
Based on aggregated 13F filings for Q4 2017.